A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Porcu, Giampiero ^a,b   Wilson, Cathal ^b   Di Giandomenico, Daniele ^b   Ragnini Wilson, Antonella ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Consorzio Mario negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AURORA A KINASE; CELL PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GGTI 298; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PEPTIDOMIMETIC AGENT; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN MAD2; RAS PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTOME; AURORA KINASE; DRUG DERIVATIVE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; MESSENGER RNA; METHIONINE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CENTROMERE; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; TRANSCRIPTION REGULATION; UPREGULATION; CHROMOSOME; DRUG ANTAGONISM; FUNGAL GENOME; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR MIMICRY; SIGNAL TRANSDUCTION;

ANIMALIA; EUKARYOTA; MAMMALIA;

CHROMOSOMES, FUNGAL; DOWN-REGULATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENOME, FUNGAL; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; METHIONINE; MOLECULAR MIMICRY; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 77954801753     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-197     Document Type: Article

References (53)

1. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292. 10.1074/jbc.271.10.5289, 8621375.
2. Tamanoi F, Mitsuzawa H. Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods Enzymol 1995, 255:82-91. full_text, 8524140.
3. Adjei AA. Farnesyltransferase inhibitors. Update on Cancer Therapeutics 2006, 1:17-23.
4. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005, 10:565-578. 10.1634/theoncologist.10-8-565, 16177281.
5. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006, 47:15-31. 10.1194/jlr.R500012-JLR200, 16278491.
6. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myleogenous leukemia. Blood 2007, 109:1387-1394. 10.1182/blood-2006-04-014357, 1794070, 17082323.
7. Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007, 6:2458-2467. 10.1158/1535-7163.MCT-06-0452, 17876043.
8. Karp JE, Lancet JE. Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics 2008, 2:491-500. 2721391, 19707379.
9. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 2009, 15:2942-2948. 10.1158/1078-0432.CCR-08-2658, 2785076, 19351752.
10. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. A tagging-via-substrate technology for detections and proteomics of farnesylated proteins. Proc Natl Acad Sci 2004, 101:12479-12484. 10.1073/pnas.0403413101, 515085, 15308774.
11. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000, 275:30451-30457. 10.1074/jbc.M003469200, 10852915.
12. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153 blocks bipolar spindle formation and chromosome alignement and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 2001, 276:16161-16167. 10.1074/jbc.M006213200, 11154688.
13. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007, 6:1317-1328. 10.1158/1535-7163.MCT-06-0703, 17431110.
14. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000, 18:927-941.
15. Raponi M, Harousseau JL, Lancet JE, Löwenberg B, Stone R, Zhang Y, Rackoff W, Wang Y, Atkins D. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2007, 13:2254-2260. 10.1158/1078-0432.CCR-06-2609, 17404110.
16. Baetz K, McHardy L, Gable K, Tarling T, Rebérioux D, Bryan J, Andersen RJ, Dunn T, Hieter P, Roberge M. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci USA 2004, 101:4525-4530. 10.1073/pnas.0307122101, 384780, 15070751.
17. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004, 116:121-137. 10.1016/S0092-8674(03)01035-3, 14718172.
18. Perlstein EO, Ruderfer DM, Roberts DC, Schreiber SL, Kruglyak L. Genetic basis of individual differences in the response to small-molecule drugs in yeast. Nat Genet 2007, 39:496-502. 10.1038/ng1991, 17334364.
19. McCue PP, Phang JM. Identification of human intracellular targets of the medicinal Herb St. John's Wort by chemical-genetic profiling in yeast. J Agric Food Chem 2008, 56:11011-11017. 10.1021/jf801593a, 2645918, 18975972.
20. Brunner TB, Hahan SM, Gupta AK, Muschel RJ, McKenna G, Bernhard EJ. Farnesyltransferase Inhibitors: An Overview of the results of preclinical and Clinical Investigation. Cancer Res 2003, 63:5656-5668.
21. Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA, Der CJ. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J Biol Chem 1994, 269:19203-19206.
22. Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, Sutherland RL. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 2003, 106:789-798. 10.1002/ijc.11263, 12866041.
23. Yamaguchi M, Zhou C, Nanda A, Zhang JH. Ras protein contributes to cerebral vasospasm in a canine double-hemorrhage model. Stroke 2004, 35:1750-1755. 10.1161/01.STR.0000129898.68350.9f, 15143294.
24. Zhang B, Groffen J, Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 2005, 106:1355-1361. 10.1182/blood-2004-09-3655, 1895195, 15860663.
25. Petronczki M, Siomos MF, Nasmyth K. Un ménage à quatre: the molecular biology of chromosome segregation in meiosis. Cell 2003, 112:423-440. 10.1016/S0092-8674(03)00083-7, 12600308.
26. Mamnun YM, Schüller C, Kuchler K. Expression regulation of the yeast PDR5 ATP-binding cassette (ABC) transporter suggests a role in cellular detoxification during the exponential growth phase. FEBS Letters 2004, 559:111-117. 10.1016/S0014-5793(04)00046-8, 14960317.
27. Wang E, Casciano CN, Clement RP, Johnson WW. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001, 61:7525-7529.
28. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007, 6:2092-2102. 10.1158/1535-7163.MCT-07-0148, 17620438.
29. Yun J, Rago C, Cheong I, Paglierini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559. 10.1126/science.1174229, 2820374, 19661383.
30. Greatrix BW, Van Vuuren HJ. Expression of the HXT13, HXT15 and HXT17 genes in Saccharomyces cerevisiae and stabilization of the HXT1 gene transcript by sugar-induced osmotic stress. Curr Genet 2006, 49:205-217. 10.1007/s00294-005-0046-x, 16397765.
31. Nourani A, Wesolowski-Louvel M, Delaveau T, Jacq C, Delahodde A. Multi-drug-resistance phenomenon in the yeast Saccharomyces cerevisiae: involvement of two hexose transporters. Mol Cell Biol 1997, 17:5453-5460. 232394, 9271421.
32. Plemper RK, Egner R, Kuchler K, Wolf DH. Endoplasmic reticulum degradation of a mutated ATP-binding cassette transporter Pdr5 proceeds in a concerted action of Sec61 and the proteasome. J Biol Chem 1998, 273:32848-32856. 10.1074/jbc.273.49.32848, 9830032.
33. Egner R, Mahé Y, Pandjaitan R, Kuchler K. Endocytosis and vacuolar degradation of the plasma membrane-localized Pdr5 ATP-binding cassette multidrug transporter in Saccharomyces cerevisiae. Mol Cell Biol 1995, 15:5879-5887. 230839, 7565740.
34. Cameroni E, Hulo N, Roosen J, Winderickx J, De Virgilio C. The novel yeast PAS kinase Rim 15 orchestrates G0-associated antioxidant defense mechanisms. Cell cycle 2004, 3:462-468.
35. Wei M, Fabrizio P, Hu J, Ge H, Cheng C, Li L, Longo VD. Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet 2008, 4:e13. 10.1371/journal.pgen.0040013, 2213705, 18225956.
36. Powers T. TOR Signaling and S6 Kinase 1: Yeast Catches Up. Cell Metabolism 2007, 6:1-2. 10.1016/j.cmet.2007.06.009, 17618850.
37. Urban J, Soulard A, Huber A, Lippman S, Mukhopadhyay D, Deloche O, Wanke V, Anrather D, Ammerer G, Riezman H, Broach JR, De Virgilio C, Hall MN, Loewith R. Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. Mol Cell 2007, 26:663-674. 10.1016/j.molcel.2007.04.020, 17560372.
38. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008, 128:980-987. 10.1038/sj.jid.5701074, 17914450.
39. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P. The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005, 280:31101-31108. 10.1074/jbc.M503763200, 16006564.
40. Fox GC, Shafiq M, Briggs DC, Knowles PP, Collister M, Didmon MJ, Makrantoni V, Dickinson RJ, Hanrahan S, Totty N, Stark MJR, Keyse SM, McDonald NQ. Redox-mediated substrate recognition by Sdp1 defines a new group of tyrosine phosphatases. Nature 2007, 447:487-492. 10.1038/nature05804, 17495930.
41. Chen RE, Thorner J. Function and regulation in MAPK signaling pathways: lessons learned from the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 2007, 1773:1311-1340. 10.1016/j.bbamcr.2007.05.003, 2031910, 17604854.
42. Hahn JS, Thiele DJ. Regulation of the Saccharomyces cerevisiae Slt2 kinase pathway by the stress-inducible Sdp1 dual specificity phosphatase. J Biol Chem 2002, 277:21278-21284. 10.1074/jbc.M202557200, 11923319.
43. Heymont J, Berenfeld L, Collins J, Kaganovich A, Maynes B, Moulin A, Ratskovskaya I, Poon PP, Johnston GC, Kamenetsky M, DeSilva J, Sun H, Petsko GA, Engebrecht J. TEP1, the yeast homolog of the human tumor suppressor gene PTEN/MMAC1/TEP1, is linked to the phosphatidylinositol pathway and plays a role in the developmental process of sporulation. Proc Natl Acad Sci USA 2000, 97:12672-12677. 10.1073/pnas.97.23.12672, 18822, 11070083.
44. Schmidt A, Schmelzle T, Hall MN. The RHO1-GAPs SAC7, BEM2 and BAG7 control distinct RHO1 functions in Saccharomyces cerevisiae. Mol Microbiol 2002, 45:1433-1441. 10.1046/j.1365-2958.2002.03110.x, 12207708.
45. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, Popescu NC. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007, 11:1185-1207. 10.1111/j.1582-4934.2007.00098.x, 17979893.
46. Francisco L, Chan CS. Regulation of yeast chromosome segregation by Ipl1 protein kinase and type 1 protein phosphatase. Cell Mol Biol Res 1994, 40:207-213.
47. Tanaka M, Ueda A, Kanamori H, Ideguchi H, Yang J, Kitajima S, Ishigatsubo Y. Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem 2002, 277:10719-10726. 10.1074/jbc.M108252200, 11790771.
48. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N. A peptidomimetic inhibitor of Farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995, 55:5302-5309.
49. Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckardt SG. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 2007, 21:739-746.
50. Wagner W, Bielli P, Wacha S, Ragnini-Wilson A. Mlc1p promotes septum closure during cytokinesis via the IQ motifs of the vesicle motor Myo2p. EMBO J 2002, 21:6397-6408. 10.1093/emboj/cdf650, 136954, 12456647.
51. Bielli P, Casavola EC, Biroccio A, Urbani A, Ragnini-Wilson A. GTP drives myosin light chain 1 interaction with the class V myosin Myo2 IQ motifs via a Sec2 RabGEF-mediated pathway. Mol Microbiol 2006, 59:1576-1590. 10.1111/j.1365-2958.2006.05041.x, 16468996.
52. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Preparation of yeast RNA. Current Protocols in Molecular Biology 1994, 2. Greene Publishing Associates and Wiley-Interscience, 13.12.1.
53. Bialek-Wyrzykowska U, Bauer BE, Wagner W, Kohlwein SD, Schweyen RJ, Ragnini A. Low levels of Ypt protein prenylation cause vesicle polarization defects and thermosensitive growth that can be suppressed by genes involved in cell wall maintenance. Mol Microbiol 2000, 35:1295-1311. 10.1046/j.1365-2958.2000.01782.x, 10760132.